Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $10.4 million.

  • Tarsus Pharmaceuticals' Gains from Investment Securities rose 4184400.0% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 176954.4%. This contributed to the annual value of -$572000.0 for FY2024, which is 13098.59% down from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Gains from Investment Securities of $10.4 million as of Q3 2025, which was up 4184400.0% from -$102000.0 recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Gains from Investment Securities registered a high of $10.4 million during Q3 2025, and its lowest value of -$3.2 million during Q4 2021.
  • Its 5-year average for Gains from Investment Securities is $997357.1, with a median of $65500.0 in 2022.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Gains from Investment Securities tumbled by 15624.28% in 2024, and later surged by 4184400.0% in 2025.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Gains from Investment Securities stood at -$3.2 million in 2021, then soared by 104.34% to $140000.0 in 2022, then surged by 1135.71% to $1.7 million in 2023, then crashed by 97.57% to $42000.0 in 2024, then surged by 24747.62% to $10.4 million in 2025.
  • Its last three reported values are $10.4 million in Q3 2025, -$102000.0 for Q2 2025, and -$125000.0 during Q1 2025.